Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 25 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Gkaliagkousi, Eugenia  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Gkaliagkousi, E., Gavriilaki E., Vasileiadis I., Nikolaidou B., Yiannaki E., Lazaridis A., et al. (2019).  Endothelial Microvesicles Circulating in Peripheral and Coronary Circulation Are Associated With Central Blood Pressure in Coronary Artery Disease.. Am J Hypertens. 32(12), 1199-1205.
Gkaliagkousi, E., Corrigall V., Becker S., de Winter P., Shah A., Zamboulis C., et al. (2009).  Decreased platelet nitric oxide contributes to increased circulating monocyte-platelet aggregates in hypertension.. Eur Heart J. 30(24), 3048-54.
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2014).  Reply to: Seeing the forest, but not the trees: pertinent considerations for examining acute changes in pulse wave velocity in response to pharmaceutical interventions and exercise.. J Clin Hypertens (Greenwich). 16(10), 769.
Gkaliagkousi, E., Anyfanti P., Chatzimichailidou S., Triantafyllou A., Lazaridis A., Aslanidis S., et al. (2018).  Association of nocturnal blood pressure patterns with inflammation and central and peripheral estimates of vascular health in rheumatoid arthritis.. J Hum Hypertens. 32(4), 259-267.
Gkaliagkousi, E., Gavriilaki E., Yiannaki E., Markala D., Papadopoulos N., Triantafyllou A., et al. (2014).  Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker.. Am J Hypertens. 27(4), 571-8.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou A., & Douma S. (2015).  Clinical Significance of Endothelial Dysfunction in Essential Hypertension.. Curr Hypertens Rep. 17(11), 85.
Gkaliagkousi, E., Doumas M., Gavriilaki E., Triantafyllou A., Vogiatzis K., Anyfanti P., et al. (2012).  Elevated levels of MMP-9 in untreated patients with stage I essential hypertension.. Clin Exp Hypertens. 34(8), 561-6.
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2014).  The enigma of microvascular and macrovascular changes in mild essential hypertension.. J Hypertens. 32(7), 1544.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou A., Nikolaidou B., Anyfanti P., Koletsos N., et al. (2018).  Asymmetric dimethylarginine levels are associated with augmentation index across naïve untreated patients with different hypertension phenotypes.. J Clin Hypertens (Greenwich). 20(4), 680-685.
Gkaliagkousi, E., Gavriilaki E., Nikolaidou B., & Douma S. (2013).  Exercise-induced platelet activation in essential hypertension: have we solved the puzzle?. J Hypertens. 31(9), 1915-6.
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2015).  Antiplatelet treatment in essential hypertension: where do we stand?. Curr Hypertens Rep. 17(4), 536.
Gkaliagkousi, E., Protogerou A. D., Argyris A. A., Koletsos N., Triantafyllou A., Anyfanti P., et al. (2020).  Contribution of single office aortic systolic blood pressure measurements to the detection of masked hypertension: data from two separate cohorts.. Hypertens Res.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou G., Nikolaidou B., & Douma S. (2014).  The putative role of vitamin D in essential hypertension: stepping into the light?. Am J Hypertens. 27(7), 985-6.
Gkaliagkousi, E., Anyfanti P., Triantafyllou A., Gavriilaki E., Nikolaidou B., Lazaridis A., et al. (2018).  Aldosterone as a mediator of microvascular and macrovascular damage in a population of normotensive to early-stage hypertensive individuals.. J Am Soc Hypertens. 12(1), 50-57.
Gkaliagkousi, E., Passacquale G., Douma S., Zamboulis C., & Ferro A. (2010).  Platelet activation in essential hypertension: implications for antiplatelet treatment.. Am J Hypertens. 23(3), 229-36.
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2015).  Effects of acute and chronic exercise in patients with essential hypertension: benefits and risks.. Am J Hypertens. 28(4), 429-39.
Gkaliagkousi, E., Anyfanti P., Lazaridis A., & Douma S. (2018).  The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension.. Ann Intern Med. 168(10), 755.
Gkaliagkousi, E., Gavriilaki E., Nikolaidou B., Triantafyllou G., & Douma S. (2014).  Exercise-induced pulse wave velocity changes in untreated patients with essential hypertension: the effect of an angiotensin receptor antagonist.. J Clin Hypertens (Greenwich). 16(7), 482-7.
Gkaliagkousi, E., Gavriilaki E., & Douma S. (2018).  Exercise-induced benefits in metabolic syndrome.. J Clin Hypertens (Greenwich). 20(1), 19-21.
Gkaliagkousi, E., Anyfanti P., Lazaridis A., Triantafyllou A., Vamvakis A., Koletsos N., et al. (2018).  Clinical impact of dipping and nocturnal blood pressure patterns in newly diagnosed, never-treated patients with essential hypertension.. J Am Soc Hypertens. 12(12), 850-857.
Gkaliagkousi, E., Douma S., Zamboulis C., & Ferro A. (2009).  Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension.. J Hypertens. 27(12), 2310-20.
Gkaliagkousi, E., Gavriilaki E., Aslanidis S., & Douma S. (2014).  Cardiovascular risk in psoriatic arthritis: should we focus on hypertension and diabetes only?. Clin Exp Rheumatol. 32(6), 995.
Gkaliagkousi, E., Anyfanti P., Lazaridis A., & Douma S. (2018).  Plasma renin activity to plasma aldosterone concentration ratio for the assessment of essential hypertensive patients in real-life clinical practice.. J Hypertens. 36(2), 444.
Gkaliagkousi, E., Gavriilaki E., Nikolaidou B., Chatzopoulou F., Anyfanti P., Triantafyllou A., et al. (2014).  Association between cardiotrophin 1 levels and central blood pressure in untreated patients with essential hypertension.. Am J Hypertens. 27(5), 651-5.
Gkaliagkousi, E., Gavriilaki E., Triantafyllou A., & Douma S. (2016).  PATHWAY-2: spironolactone for resistant hypertension.. Lancet. 387(10026), 1372.

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.